![The Weekly Break Out Ep. 22: How the US hit Iran, and spooky space moves [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/250622_b2_takeoff_USAF-scaled-e1750776866152.jpg?#)
Investors sweet on Nektar as phase 2b eczema success doubles share price
Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. The biotech reported a phase 2 win for rezpegaldesleukin in atopic dermatitis, sending its stock up 119% despite the data falling short of the bar set by Regeneron and Sanofi’s Dupixent.
Nektar Therapeutics is enjoying the sweet taste of clinical trial success after years of swallowing bitter pills. The biotech reported a phase 2 win for rezpegaldesleukin in atopic dermatitis, sending its stock up 119% despite the data falling short of the bar set by Regeneron and Sanofi’s Dupixent.
